

# ICPerMed "Best Practice in PM" Award 2018

**Gaetano Guglielmi**

Deputy General Director

Health Research

**Italian Ministry of Health**

and ICPerMed Secretariat IT-MoH Team

**M J Ruiz and M G Mancini**

**Berlin Conference, November 21st, 2018**



# ICPerMed "Best Practice in PM" Award 2018

- **Launched** on January 19th 2018. Deadline 2nd March 2018
- **Aims:** to recognize, encourage, promote and disseminate outstanding examples of Best Practices.
- **Eligibility:** only applicants from ICPerMed partner countries  
Published scientific papers and/or developed Best PM Practice strategies  
between January 1st, 2016 and December 31st, 2017
- Authors have been invited to the **ICPerMed Berlin Conference 2018** and will **present their results during today plenary session**. They will receive a non-monetary support in disseminating the respective project to the scientific community and the general public.

## Main Topic and format:

- The applications received covers one or more than one of the three defined formats:
- **1. Scientific paper** focused on novel approaches for the implementation of PM
- **2. Training programmes** for health personnel, increasing the level of awareness on the potential of PM
- **3. Examples for interdisciplinary or intersectoral groups of collaboration** (governmental and nongovernmental organizations, academic management, medical research and Health Care), for the implementation of PM, including Ethical, Legal and Social Issues (ELSI) activities

# Results Award BP 2018 - Selection Procedure

- Proposals has been evaluated by seven researchers with different expertise, with geographic and gender balance.
- **One-stage process**
- Supported by the ICPerMed Steering Board with the final approval by the ICPerMed Executive Committee.
- In brief, 18 proposals have been submitted with a total of 61 researchers.
- Proposal geographic distribution: 9 from Italy, 3 from Israel, 2 from Spain and 1 from Luxembourg ,The Netherlands, Germany and Switzerland.



## AWARD 2018

# Poster presentation

<b>BENTVELSEN Robbert</b>	<b>Leiden University Medical Center</b>	<b>The Netherlands</b>
<b>NEUMAN Tzahi</b>	<b>Hebrew University Hadassah Medical Center, Jerusalem</b>	<b>Israel</b>
<b>MUMME Marcus / BARBERO Andrea</b>	<b>Universitatsspital, Basel</b>	<b>Switzerland</b>
<b>CAPOBIANCO Enrico</b>	<b>University of Miami / CNR (ISOF) Bologna</b>	<b>USA / Italy</b>

# Posters

## **“PARTICIPATIENT – Reducing the risk of catheter-associated urinary tract infections via a smartphone application for patients”**

- **Author: BENTVELSEN Robbert, Leiden University Medical Center. The Netherlands**
- *“The Participatient app is developed in co-creation with patients, nurses, physicians and psychologists. In our pilot we demonstrated the app helps make hospital stay safer and more pleasant for patients by giving information on infection prevention (Catheter Check) and practicalities on the hospital stay. “*

## **“Value of information analysis in Personalise Medicine”.**

- **Author: CAPOBIANCO Enrico, University of Miami / CNR (ISOF) Bologna. USA / Italy**
- *Value of Information is the concept applied to two different studies in this poster by Enrico Capobianco and his co-author. The so-called Vol empowers the idea of personalised Medicine, and is here presented as central to clinical decisions assisted by quantitative models. The examples cover Catchment Area analysis and assessment of Person-centered Treatments.*

# Posters

## ***“Nasal chondrocytes-based engineered autologous cartilage tissue for repair of articular cartilage defects”***

- **Author: MUMME Marcus / BARBERO Andrea ,Universitatsspital, Basel. Switzerland**
- *The objective of our approach is to develop a new regenerative therapy based on the use of autologous nasal chondrocytes (NC) and delivered as a tissue engineered cartilage graft. We performed a phase I, prospective, uncontrolled, investigator initiated clinical trial at University-Hospital Basel (Switzerland), (ClinicalTrials.gov: NCT01605201) with the objective of demonstrating safety & feasibility for the use of engineered nasal cartilage grafts (N-TEC).*

## ***“A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana's Platform”***

- **Author : NEUMAN Tzahi, Hebrew University Hadassah Medical Center, Jerusalem. Israel**
- *Trial, showing that the Ventana platform can be used safely to stratify patients for pembrolizumab-based immunotherapy. Laboratories world-wide, which are using the Ventana platform, can safely perform the PD-L1 immunostain and treat their patients with the first-line immunotherapy for the different indications.*



- Winners 2018**

<b>First Author Name</b>	<b>Institution</b>	<b>Country</b>
<b>ALONSO SANCHEZ Angel</b>	<b>Navarrabiomed</b>	<b>Spain</b>
<b>MARTIN DE DIOS Consuelo</b>	<b>Foundacion Instituto Roche, Madrid</b>	<b>Spain</b>
<b>TODT Daniel</b>	<b>Abteilung für Molekulare und Medizinische Virologie Ruhr-Universität Bochum</b>	<b>Germany</b>



# ICPerMed "Best Practice in PM" Award 2018 Winner

## **NAGEN 1000: An example of a Project for Regional Implementation of Personalised Genomic Medicine in Healthcare**

Author : Angel ALONSO Sanchez,

NavarraBiomed. CENTRO DE INVESTIGACIÓN BIOMÉDICA. Spain.

“A project demonstrating the implementation of the Whole Genome Sequencing (WGS) derived information as a clinical tool for the development of precision medicine in the Public Health Service”

# ICPerMed "Best Practice in PM" Award 2018 Winner

## **Proposal of Recommendation for a National Strategy on Personalised Medicine Report**

- Author : Consuelo MARTIN De DIOS  
Fundación Instituto Roche. Spain

“Proposal of Recommendations for a National Personalised Precision Medicine Strategy, it is project promoted by Roche Institute Foundation with the aim of becoming a lever for a Personalised Precision Medicine National Strategy in Spain”

# ICPerMed "Best Practice in PM" Award 2018 Winner

## **In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome**

- Author : Daniel TODT

Department of Molecular and Medical Virology Ruhr-Universität Bochum  
Germany

“In this project the authors tracked down single nucleotide variants in the genome of HEV that were associated with resistance to ribavirin . These marker could be used to early identify patients at risk for treatment failure”

**FUTURE**

**Best Practise Recognition**

**ICPerMed 2019 – 2nd call**

**Personalised Medicine**

**for all citizens and patients**

**within sustainable Health Systems**

# Best Practise Recognition ICPerMed 2019 – 2nd call

Today we will launch the second  
“BEST PRACTICE IN PERSONALISED  
MEDICINE” RECOGNITION 2019.

Deadline for proposal submission will be on **21<sup>st</sup> of January, 2019.**

Opened to **applicants worldwide.**

Call topics have been aligned to **topics of Madrid Workshop 2019.**

Same Evaluation criteria and procedure as the 1<sup>st</sup> call.



# Best Practise Recognition ICPerMed 2019 – 2nd call

**We wait your applications!!!**

**For more information:**

<https://www.icpermed.eu/>

Maria Grazia Mancini

[mg.mancini-esterno@sanita.it](mailto:mg.mancini-esterno@sanita.it)

Maria Josefina Ruiz Alvarez

[mj.ruizalvarez-esterno@sanita.it](mailto:mj.ruizalvarez-esterno@sanita.it)

# Now the Floor to the Winners